Galderma raises 2026 sales guidance. Galderma stock is valued at CHF 45.0 billion

Published on 10/26/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales hit USD 4.765 billion, up 25.1 percent in nine months. Galderma stock costs EUR 208.50 on October 26, 2026.

Growth broadens across the portfolio

Galderma raised its 2026 sales growth guidance to 22.5-23.5 percent on October 22, 2026.
Therapeutic Dermatology grew 64.4 percent in the first nine months of 2026, with Nemluvio sales of USD 735 million.
Galderma stock trades at EUR 208.50 at 10:22 a.m. CEST at Lang & Schwarz on October 26, 2026.
The next report date is March 11, 2027.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma Group AG (ISIN CH1335392721) raised its 2026 sales growth guidance to 22.5-23.5 percent from 19-21 percent on October 22, 2026, while its stock was valued at CHF 45.0 billion. The higher outlook followed first-nine-month sales of USD 4.765 billion, up 25.1 percent at constant currency, according to Galderma.

Guidance rises to 22.5 percent

The October 22 update combined faster growth with a stable profitability target. Galderma confirmed full-year Core EBITDA margin guidance of 26 percent at constant currency while continuing to invest behind its portfolio.

Third-quarter sales increased 26.0 percent at constant currency to USD 1.632 billion. The official release said growth was broad based, with Injectable Aesthetics up 13.2 percent, Dermatological Skincare up 16.2 percent and Therapeutic Dermatology up 64.4 percent during the first nine months of 2026.

Three dates shaped the story

On September 30, 2026, Galderma presented three-year Nemluvio data showing that up to 91 percent of patients achieved at least 75 percent improvement in eczema severity, according to Galderma. On October 14, 2026, it signed an agreement to acquire ZO Skin Health for an enterprise value of USD 1.5 billion, as Galderma announced. The October 22, 2026 trading update then lifted the full-year growth range to 22.5-23.5 percent.

What drives the higher outlook?

Therapeutic Dermatology is the clearest growth engine. First-nine-month sales reached USD 1.347 billion, up 64.4 percent, while Nemluvio contributed USD 735 million compared with USD 263 million in the prior-year period. The company also reported third-quarter Nemluvio sales of USD 302 million.

The ZO transaction adds a strategic variable. Galderma said the deal is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals, and could be slightly dilutive to Core EBITDA margin in 2027.

Next reporting date is March 11

TradingView lists March 11, 2027, as the next Galderma earnings date. The schedule gives investors a further checkpoint for the raised sales outlook and the integration path for ZO Skin Health.

Stock price and market value

Galderma stock was trading at EUR 208.50 at Lang & Schwarz on October 26, 2026 at 10:22 a.m. CEST. The primary listing is on SIX in Zurich, where the stock was quoted at CHF 193.10 at 11:14 a.m. CEST on October 26, 2026, while the company had a market capitalization of CHF 45.0 billion as of the same date. The stock is a member of the SMI.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.